44) as a reducing agent. A peptidol can be obtained by means of a rapid reaction and only a simple filtering method; and the generation of by-products accompanying with the reaction can be reduced by changing conditions.
Provided is a cell having a reporter gene system of a dual-structure chromogenic enzyme, wherein the cell has the function of expressing a first chromogenic enzyme on the cell surface and releasing a second chromogenic enzyme. Further provided is a method for screening an object to be detected using the cell, comprising bringing the object to be detected into contact with the cell, and measuring a reaction signal of the chromogenic enzyme generated by the cell to analyze the characteristics of the object to be detected.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
3.
INTRAMEDULLARY NAIL SCREW HOLE POSITIONING APPARATUS
The present invention relates to an intramedullary nail screw hole positioning apparatus. The apparatus comprises: an intramedullary nail, which has a screw hole for a screw to be fastened, wherein the screw hole is used for allowing said screw to be implanted into the body or a bone of a subject, and the screw hole penetrates a tube wall of the intramedullary nail; a laser emitting source, which is used for emitting an incident light signal of laser light; an optical fiber tube, which includes a top portion, a light source optical fiber connected to the laser emitting source and used for guiding the laser light to be incident to the intramedullary nail of the subject, and a receiving optical fiber for receiving a reflected light signal reflected from the intramedullary nail of the subject, wherein the top portion of the optical fiber tube is in movable contact with the body or bone, into which the intramedullary nail is implanted, of the subject; and a receiving apparatus, which is connected to the receiving optical fiber, includes a detector and a power meter, and is used for detecting, measuring and displaying an energy difference ratio, wherein the energy difference ratio is the power ratio of the reflected light signal to the incident light signal.
A61B 90/13 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures pour la chirurgie stéréotaxique, p. ex. système stéréotaxique à cadre avec des guides pour aiguilles ou instruments, p. ex. des glissières courbes ou des articulations à rotule guidés par la lumière, p. ex. pointeurs lasers
4.
TREATING SPINAL MUSCULAR ATROPHY (SMA) BY MODULATING MIR34 AND USE OF MIR34 AS A PREDICTIVE BIOMARKER OF SMA
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
CHOU, Mei-Yin (USA)
Inventeur(s)
Chen, Jun-An
Jong, Yuh-Jyh
Abrégé
The present invention relates to a MiR34 as a biomarker for spinal muscular atrophy (SMA) and therapeutic/prognosis applications. In particular, the present invention provides a method for treating SMA via modulating MiR34. The present invention also provides a method for prognosis of SMA based on a baseline level of MiR34 in an SMA patient before treatment. The present invention further provides a method for predicting an SMA patient's response to treatment against SMA based on the change of a MiR34 level in the patient before and after the treatment or during the period of the treatment.
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
Inventeur(s)
Yang, Ching-Chun
Chang, Chih-Hsu
Abrégé
The present invention relates to a use of a composition for the manufacture of a drug for treating symptoms of a disease associated with an infection caused by hepatitis B virus (HBV), in particular a chronic HBV infection, in which the composition includes a CRM1 inhibitor, and the CRM1 inhibitor has the function of inhibiting a nuclear export pathway of HBV core particles.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 31/20 - Antiviraux pour le traitement des virus ADN
6.
TELLURIUM-CONTAINING COMPOUNDS AND THE USE OF TREATING BACTERIAL INFECTIONS THEREOF
A compound and the use of a pharmaceutical composition having the compound in preparation of a medicament for treating bacterial infections thereof are provided, wherein the compound is derived from AS101 and having a general formula (I) or a general formula (II).
C07D 293/02 - Composés hétérocycliques contenant des cycles comportant des atomes d'azote et de sélénium, ou d'azote et de tellure, avec ou sans atomes d'oxygène ou de soufre, comme hétéro-atomes non condensés avec d'autres cycles
C07D 293/10 - Composés hétérocycliques contenant des cycles comportant des atomes d'azote et de sélénium, ou d'azote et de tellure, avec ou sans atomes d'oxygène ou de soufre, comme hétéro-atomes condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 517/12 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes de sélénium, de tellure ou d'halogènes comme hétéro-atomes du cycle dans lesquels le système condensé contient trois hétérocycles
C07D 517/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes de sélénium, de tellure ou d'halogènes comme hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
A61K 31/095 - Composés du soufre, du sélénium ou du tellure, p. ex. thiols
A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
C08G 83/00 - Composés macromoléculaires non prévus dans les groupes
C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation
8.
CLINICAL THERAPEUTIC DRUG PREDICTION AND RECOMMENDATION SYSTEM AND METHOD FOR EVALUATING EFFICACY OF SECOND-GENERATION HORMONE DRUG IN TREATMENT OF PROSTATE CANCER
A clinical therapeutic drug prediction and recommendation system (1) for evaluating the efficacy of a second-generation hormone drug in treatment of prostate cancer, comprising: an input device (10) used for receiving an ex vivo biological sample (40) and generating a physiological signal; a computer device (20) connected to the input device (10) and comprising a processor (201) used for receiving the physiological signal, said processor comprising an analysis module (2011) which compares at least the physiological signal with patient gene sets to which treatment by a first drug and a second drug are respectively applied, and then respectively obtains a first score and a second score corresponding to the first drug and the second drug by a computation method, the scores being further compared by a comparison module (2012), when the comparison result (20121) shows that the first score is greater than the second score, an indication (20131) of recommending the first drug to the individual being given, otherwise, an indication (20132) of recommending the second drug to the individual being given; and a display device, used for displaying the recommendation indication.
The present invention relates to anti-CXCR2 antibodies that recognize CXCR2 and inhibit the activity of CXCR2, and the use of the anti-CXCR2 antibodies in the treatment of pancreatic cancer and leukemia.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A method and system for predicting a stage of diabetic nephropathy by means of ophthalmoscopic images. Ophthalmoscopic images and inspection data are used in combination for establishing a prediction model for the progression of the stage of diabetic nephropathy, thereby delaying the progression of diabetic nephropathy and reducing the probability of dialysis.
A nicotinic hydrazide derivative, a stereoisomer thereof, and a pharmaceutically acceptable salt thereof. The nicotinic hydrazide derivative has a molecular formula (I), wherein each of X, Y, and Z is one of N and CH, at least one of X, Y, and Z is CH, at least one of X, Y, and Z is N, and R is one of OH and NH2.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
C07B 43/00 - Formation ou introduction de groupes fonctionnels contenant de l'azote
A positive-pressure respirator, comprising: a tube (1), provided with an inner end hole (M) and an outer end hole (N) in communication with each other, wherein the outer end hole (N) is less than the inner end hole (M), and the tube (1) is used for being inserted into a nasal cavity; and a two-way air valve (2), which is located in the tube (1), wherein the two-way air valve (2) is axially movable between the inner end hole (M) and the outer end hole (N), and the two-way air valve (2) has a fluid channel (P) in communication with the inner end hole (M) and the outer end hole (N). The positive-pressure respirator has the effects of improving sleep quality, usage comfort, aesthetics, convenience etc.
NATIONAL HEALTH RESEARCH INSTITUTES (Taïwan, Province de Chine)
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
KAOHSIUNG CHANG GUNG MEMORIAL HOSPITAL (Taïwan, Province de Chine)
Inventeur(s)
Huang, Ming-Shyan
Wang, Chin-Chou
Wu, Chao-Chien
Zheng, Zhi-Fu
Abrégé
The present invention provides a method for diagnosing asthma by using a panel of internal lipid species, including LPE 22:6, LPE 20:4, SM 16:0, PE 16:0/22:6, PE 18:0/22:6, PE 18:0/20:4 PE 18:0/18:2, and phosphatidylcholine (PC) 18:0/18:2, comprising comparing a cutoff ratio value of the panel of internal lipid species with internal lipid species ratio value for diagnosing. The present invention also provides a method for treating asthma, comprising administrating a therapeutically effective amount of a LEP 22:6 inhibitory regulator, bovine serum albumin or human serum albumin to a subject in need thereof.
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
Inventeur(s)
Chen, Chin-Cheng
Hung, Chin-Hsien
Abrégé
Provided are methods and compositions for prevention or treatment of pain, e.g., stress- related pain. Also provided is a method for producing a non-human animal model for pain, the non-human animal model produced therefrom, and a method of screening an agent pharmaceutically active in prevention or treatment of pain using such non-human animal model.
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
15.
SLURRY FOR PHOTOCURING 3D PRINTING, PREPARATION METHOD THEREFOR, AND METHOD OF USE THEREOF
A method for preparing a slurry for photocuring 3D printing, comprising the steps of: mixing monomer molecules of a temperature-sensitive hydrogel, a photocuring initiator, a crosslinking agent, a solvent, and a ceramic material to obtain the slurry; using the slurry as a raw material, and carrying out a 3D printing procedure by a photocuring 3D printer to obtain a prototype of a 3D printed article; and oil coating the prototype of the 3D printed article, followed by heating and sintering the same, to obtain the 3D printed article.
Long non-coding DANCR (lnc-DANCR) as biomarker for the diagnosis, prognosis and monitor of cancer, including but not limited to hepatocellular carcinoma (HCC) is provided herein. In some embodiments, the method of evaluating the prognosis of hepatocellular carcinoma (HCC) in a subject comprises: isolating at least one transcript of lnc-DANCR from a biological sample of a subject; measuring the test expression level of the at least one transcript of lnc-DANCR; and evaluating the prognosis of hepatocellular carcinoma of the subject according to the comparison of the test expression level to a control expression level of the at least one transcript of lnc-DANCR. In some embodiments, a kit for evaluating the prognosis of hepatocellular carcinoma (HCC) in a subject comprises binding molecules to at least one transcript of lnc-DANCR, wherein the at least one transcript of lnc-DANCR is exosomal lnc-DANCR.
A cruciate ligament suspended internal lock fixator, which is used to solve the problem in the prior art wherein a ligament implant is prone to loosening after operation and which comprises: a hollow tube body (1) having at least one growth-inducing hole (11) and a non-return structure (14), the at least one growth-inducing hole (11) penetrating an inner wall surface (12) and an outer wall surface (13) of the hollow tube body (1), and the non-return structure (14) being located at the outer wall surface (13) of the hollow tube body (1); and a limiting member (2), which is located within the hollow tube body (1), two ends of the limiting member (2) being connected to the inner wall surface (12).
CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY (Chine)
CHANG GUNG UNIVERSITY (Chine)
KAOHSIUNG MEDICAL UNIVERSITY (Chine)
Inventeur(s)
Hwang, Tsong-Long
Chen, Yeh-Long
Tzeng, Cherng-Chyi
Tseng, Chih-Hua
Abrégé
Disclosed herein are compounds of formula (I), and pharmaceutical compositions comprising the same. The compounds of formula (I) are neutrophilic inflammation inhibitors, thus, they are useful for treatment and/or prophylaxis of inflammatory diseases and/or disorders associated with abnormal activation of neutrophils, such as ARDS, ALI, COPD, lung fibrosis, chronic bronchitis, pulmonary emphysema, α-1 anti-trypsin deficiency, cystic fibrosis, idiopathic pulmonary fibrosis, liver injury, steatohepatitis, liver fibrosis, damages caused by ischemia and reperfusion, myocardial infarction, shock, stroke, and organ transplantation, ulcerative cholitis, vasculitis, SLE, sepsis, SIRS, arthritis, psoriasis, atopic dermatitis, and inflammatory skin diseases. (I)
Disclosed are a biomedical material (1) with a synergistic effect, a manufacturing method therefor and a system comprising the biomedical material (1) with a synergistic effect. The biomedical material (1) with a synergistic effect comprises a biomedical ceramic carrier (11) with a multistage pore structure (111), wherein the biomedical ceramic carrier (11) with a synergistic effect at least contains silicon and oxygen ingredients; one nano-scaled silver particle (12) confined in the multistage pore structure (111), wherein the multistage pore structure (111) comprises one pore wall with multiple mesopores (114) and multiple large pores (112), and the pore wall separates the multiple large pores (112); and a bioactivator (13), wherein the bioactivator (13) is confined in a part of the multiple mesopores (114) or is attached to one surface of the pore wall. The biomedical material (1) is located in a system comprising microorganisms and a hydrophilic medium, and after a certain time, generates a synergistic effect and has a fractional inhibitory concentration index (FIC index) less than or equal to 0.5.
A blepharoptosis detection method and system for solving the problems that existing manual blepharoptosis detection methods are very time-consuming, and the inconsistency in measurements carried out by different doctors causing errors in measurement results. The method and system comprise: a photographing unit carrying out photography to generate an eye image; a processing unit performing image processing on the eye image to generate an edge image; the processing unit performing image computation on the eye image and the edge image to obtain multiple characteristic variables; the processing unit obtaining a characteristic parameter set according to the computation of multiple characteristic variables; and the processing unit comparing the characteristic parameter set with one piece of preset blepharoptosis information to infer the blepharoptosis severity and a levator function.
A method for preparing hyaluronic acid hydrogel microparticles and a use thereof in repairing articular cartilage defects, the method for preparing hyaluronic acid hydrogel microparticles comprising: (a) reacting hyaluronic acid with methacrylic anhydride to synthesize a methacrylated hyaluronic acid conjugate; (b) mixing the methacrylated hyaluronic acid conjugate with a photoinitiator, and irradiating ultraviolet light to carry out a photopolymerization reaction so as to obtain a hyaluronic acid hydrogel; and (c) passing the hyaluronic acid hydrogel through a sieve to obtain hyaluronic acid hydrogel microparticles.
C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
C08J 3/28 - Traitement par ondes énergétiques ou par rayonnement de particules
C08F 299/00 - Composés macromoléculaires obtenus par des interréactions de polymères impliquant uniquement des réactions entre des liaisons non saturées carbone-carbone, en l'absence de monomères non macromoléculaires
C08F 2/48 - Polymérisation amorcée par énergie ondulatoire ou par rayonnement corpusculaire par la lumière ultraviolette ou visible
In the present disclosure, a new micro-ribonucleic acid has been developed by means of mice in which a glycine N-methyltransferase has been knocked out and high-throughput sequencing. The micro-ribonucleic acid can be used to assess whether an individual is at risk of suffering from liver diseases. Accordingly, also disclosed are primers and kits which can amplify the micro-ribonucleic acid by means of a polymerase chain reaction. Further disclosed is an inhibitor which can complement micro-ribonucleic acid and which acts as a pharmaceutical composition for treating liver diseases. Further disclosed is the in situ hybridization staining of a tissue section of an organ or tissue with the micro-ribonucleic acid to assess whether an individual is at risk of suffering from other cancers.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
A composite scaffold containing a drug. The scaffold comprises a porous bone material and a drug release nanocarrier, wherein the drug release nanocarrier contains a bone growth-promoting drug, and is distributed in the porous bone material. The present invention enables a local sustained release of the drug to accelerate bone regeneration at the location of a bone defect.
Provided a lycine N-methyl transferase (GNMT) mutant gene which can prevent micro RNA has-miR-244 interference related to cancers, and which then can be used for preventing or treating liver diseases, the GNMT mutant gene being selected from a sequence shown in one of the SEQ ID NOs:3-15. Also provided is recombinant vector that is formed by carrying the GNMT mutant gene in an adeno-associated virus vector, and pharmaceutical uses thereof.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
USE OF COMPOSITION IN PREPARATION OF MEDICAMENT FOR PROMOTING INDIVIDUAL HAIR GROWTH, PREVENTING HAIR LOSS OR PROMOTING INDIVIDUAL HAIR FOLLICLE STEM CELL PRODUCTION
Disclosed in the present invention is use of a composition in the preparation of a medicament for promoting individual hair growth, preventing hair loss or promoting individual hair follicle stem cell production, the composition comprising, as a main active component, an effective amount of Derinat, which is a deoxyribonucleic acid sodium salt.
A ceramic material having the characteristics of cold isostatic pressing compression molding comprises a temperature sensing water glue and a ceramic material component. The temperature sensing water glue is combined with the ceramic material component. A method for preparing ceramics having different color levels or gradient concentrations comprises: mixing temperature sensing water glue with Zirconia ceramic powder, adding liquid salts, and increasing the stability of the mixture to a critical temperature. A gradient slurry mixing device comprises a filling tube, a top cover, a stirring member, and a material outlet end.
The present invention relates to a use of a discoidin domain receptor 1 (DDR1) inhibitor in preparing a drug for preventing or treating osteoarthritis. The present invention also relates to a use of a DDR1 activator in preparing a drug for preventing or treating a disorder related to abnormal endochondral ossification.
Disclosed in the present invention is a method for detecting a cancer or conducting cancer risk assessment, the cancer having a PREX2 manifestation of a mutation. The cancer may be a primary cancer, a metastatic cancer or a recurrent cancer. According to embodiments of the present invention, the mutation is G258V, S1113R, E1346D or K400fs. Also disclosed in the present invention is a method for treating a required individual.
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
Disclosed is an arthroscopic cannula in order to solve the problem of more wounds being created due to the use of a plurality of cannulas in a conventional arthroscopic surgery. The arthroscopic cannula comprises: a cannula body (1); a spacer (2), wherein the spacer (2) is provided inside the cannula body (1), and the spacer (2) extends axially along the cannula body (1) to divide an internal space of the cannula body (1) into a first chamber (S1) and a second chamber (S2); and a joint (3) which is connected at one end of the cannula body (1), wherein the interior of the joint (3) is in communication with the first chamber (S1) and the second chamber (S2).
A61B 1/317 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour l'introduction dans des incisions chirurgicales, p. ex. laparoscopes pour les os ou les articulations, p. ex. ostéoscopes, arthroscopes
Provided in the present invention is a use for (2R, 4R)-1,2,4-trihydroxyheptadec-16-yne or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer or an enantiomer in the preparation of a pharmaceutical composition for preventing or treating a hepatic injury.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
31.
METHOD FOR DETECTING WHETHER GLUCOSE METABOLISM IS ABNORMAL, AND PREVENTION AND TREATMENT THEREFOR
A method for detecting whether glucose metabolism is abnormal comprises: detecting GPx2 gene expression,GPx2 protein expression or the activity of GPx2 protein in a test body, and making comparisons with GPx2 expression amount of a normal individual, when the GPx2 expression of the individual is significantly lower than that of the normal individual, indicating that the carbohydrate metabolism of the individual is in an abnormal state. Applications of GPx2 in the preparation of a medical composition for the treatment and prevention of type II diabetes.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
Disclosed is a guide for a surgical purpose (10), comprising: a long columnar body (20) which has a hollow shape, an upper side of the long columnar body (20) having a semi-cylinder (21), the bottom of the long columnar body (20) having a cuboid (22), the cuboid (22) being internally provided with an elongated slot (23) in communication from head to tail, and the interior of the semi-cylinder (21) being in communication with the interior of the cuboid (22); a wing-shaped part (30) which has a wing shape, is provided at one end of the long columnar body (20), is engaged with one side of the cuboid (22) and extends from both ends of the side, and is used for grasping during surgery; a stopper (40) which has an annular shape, is sleeved on the other side of the long columnar body (20), is engaged with the other side of the cuboid (22), and is used for pressing against tissue during surgery; and a replaceable expander (50) which is disposed in the elongated slot (23), and is used for expanding a surgical incision wherein tissues are separated.
Provided is an intraosseous implant (100), a configuration of which comprises a porous matrix (101) and a sleeve (102). Also provided is a method for implanting the intraosseous implant (100), comprising: obtaining a desired three-dimensional image of a periodontal alveolar bone defect into which the intraosseous implant (100) is to be implanted; establishing a digital three-dimensional model; according to the digital three-dimensional model, fabricating the porous matrix (101) with a configuration matching the size and the type of the periodontal alveolar bone defect to be implanted; and placing the sleeve (102) into a cavity (1013) contained in the porous matrix (101).
Disclosed is a pessary for transvaginal haemostasis, wherein the radial dimension of a balloon body (1) can be changed to form a relatively large pressure on a vaginal wall, thereby achieving the effect of high-pressure haemostasis. The pessary for transvaginal haemostasis comprises: the balloon body (1), being made of an expandable material, the balloon body (1) having a cavity (11), the cavity (11) having a filling hole (12) so that a fluid can be filled into or drawn out of the cavity (11) through the filling hole, the balloon body (1) having a first end (1a) and a second end (1b), the balloon body (1) having at least one hollow passage (13), the passage (13) running through the first end (1a) and the second end (1b) of the balloon body (1) and not being in communication with the cavity (11), an outer surface of the balloon body (1) having at least one channel (14), and the channel (14) also running through the first end (1a) and the second end (1b) of the balloon body (1); and a support body (2) having a coupling end (2a) and a support end (2b), the coupling end (2a) being coupled to the second end (1b) of the balloon body (1), the support body (2) having a through hole (21) in communication with the passage (13), and the peripheral surface of the support body (2) having at least one recessed portion (22) corresponding to the channel (14).
Provided is a device for rapidly isolating cells from tissue, comprising: a stirring and cutting member, having a rotary cutting tool, wherein same is driven by a motor so as to rotate to stir and cut tissue, and can inject digestive enzymes to accelerate decomposition of the tissue; and double-layered nested cups comprising an inner cup and an outer cup, used for accommodating and filtering solution of required cells, wherein a filter device of the inner cup screens out the required cells, and the outer cup collects the filtered solution.
A pyrazolylquinoline compound comprises: a quinolinyl group attached to a substituent R1 at the C6 position, wherein the R1 is a halogen atom; a pyrazolyl group; a first phenyl group; and a second phenyl group, wherein the C2 position of the quinolinyl group is attached to the C3 or C5 position of the pyrazolyl group. In the first case where the C2 position of the quinolinyl group is attached to the C3 position of the pyrazolyl group, the C5 position of the pyrazolyl group is attached to the C4 position of the first phenyl group. In the second case where the C2 position of the quinolinyl group is attached to the C5 position of the pyrazolyl group, the C3 position of the pyrazolyl group is attached to C4 position of the first phenyl group, and the N1 position of the pyrazolyl group is attached to the C4 position of the second phenyl group.
A data encryption and decryption system and an encryption and decryption method thereof. The system comprises a verification and key generation module (1), an encryption and decryption module (2), a deconstruction and reconstruction module (3) and a database module (4), wherein the encryption and decryption module (2) is coupled to the verification and key generation module (1), the deconstruction and reconstruction module (3) is coupled to the encryption and decryption module (2), the database module (4) is coupled to the deconstruction and reconstruction module (3), and the deconstruction and reconstruction module (3) deconstructs a complete ciphertext into a plurality of fragments of ciphertexts by using a deconstruction algorithm, and then stores the plurality of fragments of ciphertexts respectively into a plurality of sub-databases of the database module. By means of the encryption and decryption method performed by the system, the privacy and security of data can be improved.
A method for additive manufacturing of 3D-printed articles, comprising: (a) depositing one or more layers of slurry by printing using a 3D printer, the slurry comprising a composition of ceramic powder; (b) further pouring oil at the circumference of the one or more layers of slurry, the height of the poured oil being less than the height of the slurry; (c) repeating steps (a) and (b) until obtaining a body with a certain geometric shape as required; and (d) heating to sinter the body to obtain a 3D-printed article, wherein the 3d printer has a print carrier temperature of 30 to 80°C.
B29C 64/00 - Fabrication additive, c.-à-d. fabrication d’objets en trois dimensions [3D] par dépôt additif, agglomération additive ou stratification additive, p. ex. par impression en 3D, stéréolithographie ou frittage laser sélectif
B29C 67/00 - Techniques de façonnage non couvertes par les groupes , ou
C04B 38/00 - Mortiers, béton, pierre artificielle ou articles de céramiques poreuxLeur préparation
39.
APPLICATION OF AVOCADO EXTRACT, AVOCADENOL B, AND (2R,4R)-1,2,4-TRIHYDROXY HEPTADEC-16-YNE, AND HEALTH FOOD COMPRISING AVOCADO EXTRACT
Disclosed is application of an avocado extract to preparation of health food or a food additive for preventing virus infection of a Flaviviridae family. The present invention also provides application of avocadenol B and (2R,4R)-1,2,4-trihydroxy heptadec-16-yne to preparation of drugs for treating or preventing virus infection of a Flaviviridae family. The present invention further provides health food for inhibiting the virus replication activity or viral inflammatory response of a Flaviviridae family, comprising an effective dose of avocado extracts serving as active ingredients and pharmaceutically acceptable carriers.
Disclosed is a composition for separating adipose tissue-derived stromal cells, comprising 0.5-8% (v/v) of a first type collagenase; 0.1-0.6% (v/v) of a trypsin; and 0.01-0.2% (v/v) of a metal ion chelating agent. Disclosed is a method of separating adipose tissue-derived stromal cells, comprising obtaining an adipose tissue; treating the adipose tissue with the above composition; centrifuging the adipose tissue; and separating the adipose tissue to obtain adipose tissue-derived stromal cells. The composition and method contribute to the future rapid separation of interstitial cells in the operating room in a short period of time, and are used in regenerative medicine.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
41.
MULTI-AXIS LOAD BEARING AND GRAVITY CENTER MEASURING DEVICE
A multi-axis load bearing and gravity center measuring device comprises a first bearing plate (2), a second bearing plate (3), a connecting plate (4) and multiple third sensing elements (5). The first bearing plate (2) further includes a first sliding element (21a, 21b) and a first pressure sensing element (22). The second bearing plate (3) further includes a second sliding element (31a, 31b) and a second pressure sensing element (32). The connecting plate (4) is connected with the first sliding element (21a, 21b), the first pressure sensing element (22), the second sliding element (31a, 31b) and the second pressure sensing element (32) respectively. The third sensing elements (5) are connected with the first bearing plate (2). The device measures the pressure change of axis X, axis Y and axis Z through the first, the second and the third sensing elements respectively to measure the load bearing, the balance degree and the gravity center. The device can replace the high unit price electronic three dimensional sensors and is convenient to maintain.
Provided are oligodeoxyribonucleotides, or locked nucleic acid (LNA) -modified, and phosphorothioated (PS) bond-modified oligonucleotides directing to anti-sense microRNA-328. Also provided is a pharmaceutical composition comprising the anti-sense microRNA-328 composition and a pharmaceutically acceptable carrier. Further provided is a method for preventing or treating myopia by administering to a subject the anti-sense microRNA-328 composition.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
43.
USE OF PHARMACEUTICAL COMPOSITION IN PREPARATION OF DRUG FOR PROMOTING CHONDROCYTE GENERATION
The present invention relates to a use of a pharmaceutical composition in the preparation of a drug for promoting chondrocyte generation, wherein the pharmaceutical composition comprises a hyaluronic acid mixture and a statin compound.
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
Inventeur(s)
Chen, Yeh-Long
Cheng, Tian-Lu
Tzeng, Cherng-Chyi
Tseng, Chih-Hua
Cheng, Ta-Chun
Cheng, Kai-Wen
Luo, Wei-Fen
Abrégé
The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota β-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.
A01N 43/42 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons condensés avec des carbocycles
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
HUANG, Alice Y. (USA)
Inventeur(s)
Chen, Hui-Ting
Hsieh, Kuang-Chan
Kao, Chai-Lin
Chang, Je-Ken
Ho, Mei-Ling
Abrégé
A method for treating low bone mineral density associated with osteopenia, osteoporosis, and other diseases is disclosed. The method comprises administrating a composition comprising a 3,5-dihydroxypentanoic acid derivative according to Formula I to a mammal. A compound of 3,5-dihydroxypentanoic acid derivative having a structure according to Formula I or Formula II is also disclosed.
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A01N 37/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
47.
COMPOSITION FOR TREATING METABOLIC SYNDROME AND PREPARATION METHOD THEREFOR
A composition for treating diabetes and a metabolic syndrome comprises a six-carbon unit-three carbon unit-six-carbon unit (C6-C3-C6) compound that is represented by the following formula. R1 and R2 are H, and C3 is of a single bond structure.
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
Inventeur(s)
Cheng, Tien-Lu
Kao, Chien-Han
Chen, Bing-Mae
Su, Yu-Cheng
Tung, Hsin-Yi
Abrégé
Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
Inventeur(s)
Lin, Chun-Ching
Lin, Liang-Tzung
Richardson, Christopher D.
Hsu, Wen-Chan
Abrégé
The present invention discloses a silibinin nanoparticle comprising the compound silibinin and a hydrophilic polymer. Moreover, the silibinin nanoparticle is in form of a spherical structure with a particle size of 50 to 200 nm. The present invention also discloses a use of the silibinin nanoparticle to suppress hepatitis C virus infection and a method of treating hepatitis C, by administering the silibinin nanoparticle to a subject in need.
A01N 43/32 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec plusieurs hétéro-atomes des cycles à six chaînons
A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine
A61K 31/35 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
Inventeur(s)
Lu, Chi-Yu
Lee, Yi-Hsuan
Abrégé
The invention discloses a method for monitoring level of paraben comprising: dissolving a sample in a solvent and obtaining a supernatant containing paraben by ultrasonic vibration and high speed centrifugation; performing a derivatization reaction between a derivatization reagent and paraben by adding the derivatization reagent into the supernatant to obtain a derivatization solution containing a tagged paraben; extracting the derivatization solution by an extractant to obtain an extract containing the tagged paraben; and ionizating the tagged paraben by a laser beam and analyzing mass-to-charge ratio of the tagged paraben by an analyzer to determine molecular weight thereof.
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
Inventeur(s)
Yu, Ming-Lung
Chuang, Wan-Long
Dai, Chia-Yen
Chou, Wen-Wen
Abrégé
A method for evaluating the therapeutic efficacy of interferon(IFN)/ribavirin(RBV) for hepatitis C is disclosed. The method includes the steps of providing a specimen; mixing the specimen, a primer of a miRNA Let-7g and a poly-chain reaction(PCR) reagent together; and evaluating the efficacy of IFN/RBV on inhibiting a hepatitis C virus according to the expressing level of the miRNA Let-7g in the specimen detected by the PCR reagent.
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
HUANG, Alice Y. (USA)
Inventeur(s)
Lin, Chun-Ching
Lin, Liang-Tzung
Richardson, Christopher D.
Yen, Ming-Hong
Chung, Chueh-Yao
Abrégé
This invention relates to a pharmaceutical composition having saikosaponin as a main component, the use of the pharmaceutical composition, as well as the preparation method thereof, wherein the pharmaceutical composition is used to prevent or treat the infection of one virus selected from the hepatitis C virus, the measles virus, the respiratory syncytial virus, the vesicular stomatitis virus, the dengue virus, and the non-enveloped viruses.
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
Inventeur(s)
Cheng, Tian-Lu
Chuang, Chih-Hung
Ko, Hsiu-Fen
Lu, Yun-Chi
Abrégé
Disclosed herein is a hinge antibody capable of being selectively activated in a target cell or tissue to treat a condition therein. The hinge antibody includes a functional antibody, two inhibitory domains and four cleavable linkers. The functional antibody is capable of treating the condition in an activated state, and has two light chains and two heavy chains. Each inhibitory domain includes a hinge domain of an immunoglobulin and consists of two peptide arms. Each cleavable linker includes a peptide substrate cleavable by an enzyme specifically or highly expressed in the target cell or tissue, and connects one of the peptide arms of the inhibitory domains to the N-terminal of one of the light chains and heavy chains of the functional antibody. Also disclosed herein are methods for preparing and using this hinge antibody.
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
Inventeur(s)
Juo, Suh-Hang, H.
Wang, Yung-Song
Cheng, Hsin-Yun
Abrégé
The invention relates to a method for providing neuroprotection comprising administering to a subject an effective amount of a miRNA or a variant thereof. By providing neuroprotection,, stroke or ischemic stroke can be prevented and/or treated.
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
HUANG, ALICE Y. (USA)
Inventeur(s)
Wu, Yang-Chang
Chang, Fang-Rong
Hsieh, Tusty-Jiuan
Du, Ying-Chi
Tsai, Yi-Hong
Hsieh, Chi-Ting
Abrégé
Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.
A01N 35/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant deux liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. un radical aldéhyde
Disclosed herein are novel 4-anilinofuro[2,3-b]quinoline derivatives of formula (I), or a pharmaceutically acceptable salt thereof, wherein each of the substituents is given the definition as set forth in the Specification and Claims. Also disclosed are the preparation processes of these derivatives and their uses in the manufacture of pharmaceutical compositions and in the treatment of cancers.
A61K 31/4738 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques
C07D 491/00 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus dans les groupes , , ou
57.
PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF
A series of quaternary piperazinium salts including a structure of formula (I) or (II) are provided. In formula (I) or (II), RX represents a mineral acid, an organic acid or a commercial drug containing a carboxyl moiety selected from a group consisting of the statins, the fibric acid derivatives for lowering blood lipid, the NSAIDs, the anti-asthmatic drug, the anti-diabetic drug and the prostacyclin, which can be ionically bonded with piperazine moiety. The quarternary piperazinium salts of KMUP compounds can be used as prodrugs and have multiple therapeutic functions.
C07D 473/08 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'oxygène, de soufre ou d'azote liés directement en positions 2 et 6 deux atomes d'oxygène avec des radicaux contenant uniquement des atomes d'hydrogène et de carbone, liés en position 1 ou 3 avec des radicaux méthyle en positions 1 et 3, p. ex. théophylline
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
58.
USE OF LEPTIN IN ENHANCING THERAPEUTIC EFFICACY OF MEDROXYPROGESTERONE ACETATE ON LIVER CANCER
Use of leptin in enhancing the effect of medroxyprogesterone acetate on inhibition of hepatocarcinoma cells. When the level of leptin in hepatoma patients is higher, medroxyprogesterone acetate is administrated directly or combined with leptin. When the level of leptin in patients is lower, 5-hydroxy tryptophan is administrated for increasing the level of leptin, and then medroxyprogesterone acetate is administrated.
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
59.
EXTRACT OF TOONA SINENSIS FROM SUPERCRITICAL FLUID EXTRACTION FOR TREATING DIABETES AND METABOLIC DISEASES, THE PREPARATION METHOD AND THE USE THEREOF
KAOHSIUNG MEDICAL UNIVERSITY (Taïwan, Province de Chine)
Alice Y. HUANG (USA)
Inventeur(s)
Lein, Pei-Jung
Sun, Chuan-Chia
Kuo, Tzu-Chen
Yang, Sheng-Chung
Wu, Yang-Chang
Chang, Fang-Rong
Hsieh, Tusty-Jiuan
Tsai, Yi-Hung
Du, Ying-Chi
Abrégé
The Toona sinensis extract of the present invention is prepared using supercritical fluid technique, wherein the method includes steps of: (a) drying the leaves of T. sinensis; (b) pulverizing the leaves as particles; and (c) extracting the particles with supercritical carbon dioxide to obtain the T. sinensis extract. This supercritical T. sinensis extract not only can decrease blood sugar level, but also promotes lipid degradation, inhibits the formation of huge lipid droplet and improves the metabolic symptoms. Accordingly, the T. sinensis extract further is able to be prepared as food supplement and pharmaceuticals.
A method for treating early-stage osteoarthritis in an animal is provided. The method comprises delivery of a therapeutically effective amount of a parathyroid hormone (PTH) or a PTH derived substance to an affected joint cavity of the patient. Methods for inhibiting articular chondrocytes apoptosis and for inhibiting a degenerative process of articular chondrocytes in an afflicted animal are also provided.
brevets